Centro de Investigación Médica Aplicada-ko ikertzaileekin lankidetzan egindako argitalpenak (34)

2024

  1. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

2022

  1. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  2. Hepatic progenitor cells, senescence and IL-6 as the main players in combined hepatocellular-cholangiocarcinoma development

    Journal of Hepatology

  3. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma

    International Journal of Molecular Medicine, Vol. 49, Núm. 5

  4. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  5. SLU7: A New Hub of Gene Expression Regulation—From Epigenetics to Protein Stability in Health and Disease

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  6. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  2. Epigenetic biomarkers for the diagnosis and treatment of liver disease

    Cancers, Vol. 13, Núm. 6, pp. 1-15

  3. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  4. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge

    Oncogene, Vol. 40, Núm. 23, pp. 4033-4049

  5. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

2020

  1. Chromatin dynamics during liver regeneration

    Seminars in Cell and Developmental Biology, Vol. 97, pp. 38-46

  2. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  3. Epigenetic mechanisms in gastric cancer: Potential new therapeutic opportunities

    International Journal of Molecular Sciences, Vol. 21, Núm. 15, pp. 1-21

  4. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

    Cells, Vol. 9, Núm. 10

  5. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg

    JHEP Reports, Vol. 2, Núm. 6

  6. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

2019

  1. Epigenetic mechanisms in hepatic stellate cell activation during liver fibrosis and carcinogenesis

    International Journal of Molecular Sciences, Vol. 20, Núm. 10

  2. Splicing events in the control of genome integrity: Role of SLU7 and truncated SRSF3 proteins

    Nucleic Acids Research, Vol. 47, Núm. 7, pp. 3450-3466